Nexentis Seeks Approval for $10M Convertible Note Facility and 20M-Share Blanket Issuance
NXTS is trading near its 52-week low of $0.599 (3.3% above the low) on light trading volume (0.1× avg).
Summary
Nexentis' annual proxy asks shareholders to approve a $10M convertible note facility on dilutive variable-price terms and a blanket 20-million-share issuance authority, alongside ratification of Deloitte as its new auditor.
Key Events · Financing and Capital Events · NXTS
-
Convertible Note Facility Proposed
Up to $10M principal with a single investor; initial $1.5M note sold for $1.35M (10% OID), 8% interest rising to 14% on default, 28-month maturity, quarterly draws capped at $1.5M starting January 1, 2027.
-
Variable-Price Conversion Terms
Notes convert at the lower of the pre-approval closing price or 88% of the 20-day VWAP, floored at 20% of the fixed price; warrants for 100% of conversion shares at 80% of the fixed price; 4.99% commitment shares issued at closing.
-
Blanket 20M-Share Issuance Authority
Proposal 2 authorizes up to 20,000,000 shares for up to $100 million in non-public offerings at discounts up to 20%, exercisable through the three-month anniversary of the December 14, 2026 meeting.
-
Deloitte Auditor Ratification
Shareholders vote on Brightman Almagor Zohar & Co. (Deloitte) for FY2026, following the August 6, 2026 dismissal of Somekh Chaikin (KPMG); KPMG's prior reports carried a going-concern paragraph.
Analysis · NXTS · Life Sciences
At its December 14 annual meeting, Nexentis is asking shareholders to pre-approve two large capital-raising channels: a blanket authority to issue up to 20 million shares for up to $100 million at discounts of up to 20%, and a specific convertible note facility of up to $10 million with a single investor. The note terms are punitive: a 10% original issue discount, conversion at 88% of the 20-day VWAP with a floor at 20% of the fixed price, warrants for 100% of conversion shares struck at 80% of the fixed price, and 4.99% commitment shares issued up front. Against 2,962,073 shares outstanding, the 20 million-share authorization is enormous relative to the current share count, and the variable-price conversion means a falling stock price mechanically issues more shares. This comes after a Nasdaq deficiency notice for failing the $2.5M stockholders' equity test (September 3) and a going-concern warning reiterated in the Q2 10-Q — the company needs equity, and these are the terms it can get. Shareholders are also asked to ratify Deloitte as auditor, replacing KPMG Israel, which was dismissed August 6.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 37.4% of the 952 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTS was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $899.6K. The 52-week trading range was $0.60 to $30.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.